文献速递头痛与眩晕帕金森病与运动障碍

接受onabotulinumtoxinA治疗患者的妊娠结局:29年累积安全性更新

Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update.
PubMed 文献 · Neurology · 2023-05-03

基于Allergan全球安全性数据库1990至2018年的29年回顾性分析,评估妊娠期或受孕前3个月内暴露于onabotulinumtoxinA的913例妊娠。在195例前瞻性妊娠的197个胎儿中,152例(77.2%)活产,4例异常结局,总体胎儿缺陷患病率2.6%(4/152,95%CI 1.0%-6.6%),重大胎儿缺陷患病率0.7%(1/152,95%CI 0.1%-3.6%),与一般人群报告的3%-6%背景率一致。

要点

  • 913例妊娠中397例(43.5%)结局已知,195例前瞻性妊娠中152例活产。
  • 活产中重大胎儿缺陷患病率0.7%(1/152,95%CI 0.1%-3.6%),与一般人群3%-6%背景率一致。
  • 总体胎儿缺陷患病率2.6%(4/152,95%CI 1.0%-6.6%),多数暴露在受孕前或早孕期。

核心结论

  • 尽管存在上市后数据库回顾固有的报告偏倚,这项29年回顾性安全性分析显示活产中重大胎儿缺陷患病率与一般人群报告率一致。
  • 虽然中孕期和晚孕期暴露数据有限,此更新扩展的安全性分析为医疗提供者和患者提供了重要真实世界证据。

研究设计与样本

  • 回顾性分析,检索Allergan全球安全性数据库1990年1月1日至2018年12月31日的数据。
  • 纳入妊娠期或受孕前≤3个月接受onabotulinumtoxinA治疗的女性(<65岁或年龄未知),评估仅来自前瞻性妊娠活产的出生缺陷患病率。
  • 共913例妊娠,397例(43.5%)结局已知且符合条件;195例前瞻性妊娠含197个胎儿。

主要发现

  • 215例已知母亲年龄的妊娠中45.6%为35岁或以上;340例已知适应症的妊娠中最常见为美容(35.3%)和偏头痛/头痛(30.3%)。
  • 318例已知暴露时间的妊娠中94.6%在受孕前或早孕期;242例已知剂量的妊娠中83.5%暴露于<200 U。
  • 195例前瞻性妊娠197个胎儿中,活产152例(77.2%),胎儿丢失45例(22.8%;自然流产32例,人工流产13例)。
  • 152例活产中148例(97.4%)结局正常,4例异常(1例重大出生缺陷、2例轻微胎儿缺陷、1例出生并发症)。
  • 总体胎儿缺陷患病率2.6%(4/152,95%CI 1.0%-6.6%),重大胎儿缺陷0.7%(1/152,95%CI 0.1%-3.6%;一般人群3%-6%)。

关键数值与推荐

  • 证据分类:本分析提供Class III数据,表明宫内onabotulinumtoxinA暴露后活产中重大胎儿缺陷患病率与报告的背景率相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于上市后数据库回顾的性质,存在报告偏倚。
  • 中孕期和晚孕期暴露的数据有限。
  • 仅评估了前瞻性妊娠活产的出生缺陷患病率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: A previous publication of pregnancy outcomes in onabotulinumtoxinA-exposed mothers demonstrated that the prevalence of major fetal defects (0.9%, 1/110) was comparable with background rates in the general population. There is continued interest to better understand the safety of onabotulinumtoxinA during pregnancy. This analysis evaluated pregnancy outcomes after onabotulinumtoxinA exposure to provide a cumulative 29-year update. METHODS: The Allergan Global Safety Database was searched from January 1, 1990, to December 31, 2018. Data from women (younger than 65 years or unknown) during pregnancy or ≤3 months before conception treated with onabotulinumtoxinA were assessed to estimate birth defect prevalence rates of live births only from prospective pregnancies. RESULTS: Of 913 pregnancies, 397 (43.5%) were eligible with known outcomes. Maternal age was known in 215 pregnancies: 45.6% were 35 years or older. Indication was known in 340 pregnancies: most frequent were aesthetic (35.3%) and migraine/headache (30.3%). The timing of exposure was known in 318 pregnancies: 94.6% were before conception or during the first trimester. OnabotulinumtoxinA dose information was known in 242 pregnancies; most (83.5%) were exposed to <200 U. Of 195 prospective pregnancies with 197 fetuses, there were 152 (77.2%) live births and 45 (22.8%) fetal losses (32 spontaneous, 13 elective). Of 152 live births, 148 (97.4%) had normal outcomes and 4 had abnormal outcomes. Among the 4 abnormal outcomes, there were 1 major birth defect, 2 minor fetal defects, and 1 birth complication. The prevalence rate for overall fetal defects was 2.6% (4/152, 95% CI 1.0%-6.6%) and 0.7% (1/152, 95% CI 0.1%-3.6%) for major fetal defects (3%-6% in the general population). Among cases of live births and known determinable exposure times, there was 1 birth defect with preconception exposure and 2 with first-trimester exposure. DISCUSSION: Although subject to reporting bias due to the nature of the postmarketing database review, this 29-year retrospective analysis of safety data in pregnant women exposed to onabotulinumtoxinA demonstrates that the prevalence rate of major fetal defects among live births is consistent with the rates reported in the general population. Although there are limited data available for second-trimester and third-trimester exposure, this updated and expanded safety analysis provides important real-world evidence to health care providers and their patients. CLASSIFICATION OF EVIDENCE: This analysis provides Class III data that demonstrate that the prevalence rate of major fetal defects among live births subsequent to in utero onabotulinumtoxinA exposure is comparable with the reported background rates.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update. Neurology. 2023. PMID: 37137724. doi:10.1212/WNL.0000000000207375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。